This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER

This study has been completed.
Information provided by (Responsible Party):
St. Jude Medical Identifier:
First received: December 20, 2007
Last updated: March 16, 2015
Last verified: March 2015
The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.

Condition Intervention Phase
Membranous Ventricular Septal Defects Device: AMPLATZER Membranous VSD Occluder Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by St. Jude Medical:

Primary Outcome Measures:
  • Closure of perimembranous Ventricular Septal Defects [ Time Frame: 5 years ]

Enrollment: 35
Study Start Date: September 2003
Study Completion Date: September 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Device: AMPLATZER Membranous VSD Occluder
Device closure with the AMPLATZER Membranous VSD Occluder


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hemodynamically significant Perimembranous ventricular septal defects

Exclusion Criteria:

  • Patients < 8 kg
  • Supracristal ventricular septal defects
  • Left ventricle to right atrium shunting
  • Prolapse of the aortic valve
  • Right to left shunting through the defect
  • Perimembranous VSD with an aneurysm and multiple shunts which can not be successfully closed with one device
  • Patients with <2mm aortic rim
  • Sepsis (local/generalized)
  • Complex heart lesions such as atrioventricular canal defect or Tetralogy of Fallot.
  • Patients who are ASA intolerant
  • Unable to be followed for the duration of the clinical trial
  • Inability to obtain informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00578708

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University Medical Center
St. Louis, Missouri, United States, 63110
United States, Nebraska
Children's Hospital UN/CU)
Omaha, Nebraska, United States, 68114
United States, New York
Columbia University
New York, New York, United States, 10032
United States, Ohio
Columbus Children's Hospital
Columbus, Ohio, United States, 43205
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
St. Jude Medical
  More Information

Responsible Party: St. Jude Medical Identifier: NCT00578708     History of Changes
Other Study ID Numbers: AGA-008
Study First Received: December 20, 2007
Last Updated: March 16, 2015

Keywords provided by St. Jude Medical:

Additional relevant MeSH terms:
Heart Septal Defects
Heart Septal Defects, Ventricular
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities processed this record on July 24, 2017